Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

NCT04027387
View directory record Official record
Conditions
HIV-1-infection
Interventions
TMB-365
Biological
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 17, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

MYTHS - MYocarditis THerapy With Steroids

NCT05150704
View directory record Official record
Conditions
Myocarditis Acute
Interventions
Methylprednisolone, saline solution
Drug
Lead sponsor
Niguarda Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
San Diego, California • Houston, Texas • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 17, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

NCT00327444
View directory record Official record
Conditions
Ovarian Neoplasms, Ascites
Interventions
aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Oral vs IV Sedation for Cataract Surgery in Older Adults

NCT07154147
View directory record Official record
Conditions
Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions
Alprazolam, Midazolam
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 7:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

NCT01755858
View directory record Official record
Conditions
Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
Interventions
Bendavia, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 17, 2026, 7:59 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

NCT05456854
View directory record Official record
Conditions
Metabolic Disease
Interventions
Hyperglycemic Clamp, Kisspeptin-10, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 7:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

NCT00822341
View directory record Official record
Conditions
Healthy
Interventions
TG-0054
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 17, 2026, 7:59 AM EDT
Not listed Phase 3 Interventional

Non-inferiority Trial of Oral Tranexamic Acid vs. Intravenous Tranexamic Acid in Joint Replacement Surgery

NCT02438566
View directory record Official record
Conditions
Osteoarthritis, Blood Loss, Surgical, Blood Loss, Postoperative
Interventions
Tranexamic Acid (Oral), Tranexamic Acid (Intravenous)
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

NCT04988035
View directory record Official record
Conditions
COVID-19
Interventions
Danicopan, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 7:59 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00103740
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
10
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

NCT02468674
View directory record Official record
Conditions
Sarcopenia
Interventions
bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

NCT01579513
View directory record Official record
Conditions
Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions
Methylprednisolone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Up to 30 Days
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Interactive Effects of IV Ethanol and IV Nicotine

NCT01814410
View directory record Official record
Conditions
Healthy
Interventions
Intravenous ethanol placebo plus nicotine infusions, intravenous ethanol 40mg% plus nicotine infusions, intravenous ethanol 100mg% plus nicotine infusions
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab IV, risankizumab SC, risankizumab IV
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
114
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281, Placebo
Drug · Other
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

NCT02586233
View directory record Official record
Conditions
Acute Ischemic Stroke, Thrombotic Disease
Interventions
DS-1040b, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

NCT01279538
View directory record Official record
Conditions
Kidney Transplantation
Interventions
bleselumab, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 17, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 17, 2026, 7:59 AM EDT